Loading...
| Jan 01, 1970 | Daily Report |
| RISING BHARAT | News Count (102633) | |
20391. Mexico Grants Authorisation For Emergency Use Of India's Covaxin Vaccine
India Fights Corona: Vaccination Drive and Initiatives
English
Mexico
NDTV
|
- The Mexico Federal Commission for the Protection Against Sanitary Risk (Cofepris) on Wednesday has granted authorization for the emergency use of India's first domestically-produced COVID-19 vaccine, Covaxin.
- "The decision by Cofepris to authorize the emergency use of the Covaxin vaccine produced in India was made very timely. Mexico's COVID-19 vaccination opportunities are expanding," Mexican Foreign Minister Marcelo Ebrard said in a tweet
- Currently, there are five different vaccines that are being used in Mexico, either purchased from abroad or produced locally--Pfizer/BioNTech, Oxford/AstraZeneca, Sinovac, Cansino, and Sputnik V.
20392. Russia's Sputnik V Vaccine May Receive Authorisation in India Soon: Top Govt Sources
India Fights Corona: Vaccination Drive and Initiatives
English
India
News18
|
- Russia’s Sputnik V vaccine against Covid-19 may receive authorisation in India very soon, top government sources told CNN-News18.
- There is no shortage of vaccines, and the shots are being replenished every third day for every state depending on their geographical location, the sources said.
- They added that there was no data to suggest it was young people driving the second wave, but more anecdotal evidence from states like Punjab and Gujarat.
- On the vaccine eligibility being reduced, the sources said the government has constantly expanded the vaccination eligibility, and there was possibility of adding more age groups soon.
20393. Johnson & Johnson set to begin India trial of its single-shot vaccine soon
India Fights Corona: Vaccination Drive and Initiatives
English
India
Indian Express
|
- US pharma giant Johnson & Johnson, the only manufacturer with a single-dose Covid-19 vaccine, has communicated to the Indian regulator that it will soon begin bridging clinical trials in the country.
- India is looking to ramp up its vaccine doses amidst high demand due to the second surge of coronavirus in the country, with several states saying they are running out of supplies
- “Johnson & Johnson has sent a letter to the CDSCO (Central Drugs Standard Control Organisation) that they will very shortly apply for permission to conduct clinical bridging trials in India,” the sources said.
- In India, J&J has tied up with Biological E to expand manufacturing capabilities of its vaccine candidate.
- The company started delivering the single-shot vaccine towards the end of March, with the US announcing a roadmap to immunise its entire adult population.
20394. India to have 5 more COVID vaccines by Oct, Sputnik expected to get emergency use nod in 10 days
India Fights Corona: Vaccination Drive and Initiatives
English
India
ANI
|
- As more and more states flag shortage of COVID-19 vaccine doses, the Central government has pressed the accelerator to scale up vaccine production manifold.
- Top government sources told ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin.
- "India currently has 2 COVID-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021. These vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy's), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila's vaccine, and Bharat Biotech's Intranasal Vaccine.
- Safety and efficacy are the Union government's primary concerns while granting emergency use authorisation (EUA) to any COVID-19 vaccine in the country."
- Out of almost 20 COVID-19 vaccines in various clinical and pre-clinical stages, Sputnik V vaccine will get the nod first. It is expected that Sputnik is likely to get the EUA within the next ten days.
- The government is taking all steps to augment vaccine production and availability in India. A decision has been taken at the highest level to ensure all steps are taken to help domestic manufacturers to scale up vaccine production manifold.
20395. भारत को मिलेगी कोरोना की तीसरी वैक्सीन, स्पूतनिक-V को एक्सपर्ट कमेटी की मिली मंजूरी
India Fights Corona: Vaccination Drive and Initiatives
Hindi
India
Aaj Tak
|
- भारत में अब एक और वैक्सीन को मंजूरी मिल गई है. सोमवार को वैक्सीन मामले की सब्जेक्ट एक्सपर्ट कमेटी (SEC) ने रूस की स्पुतनिक वी को मंजूरी दे दी है. यानी अब भारत में इस वैक्सीन का इस्तेमाल किया जा सकेगा.
- भारत में स्पुतनिक वी हैदराबाद की डॉ. रेड्डी लैब्स के साथ मिलकर ट्रायल किया है और उसी के साथ प्रोडक्शन चल रहा है.
- स्पुतनिक वी की सफलता का प्रतिशत 91.6 फीसदी रहा है, जो कंपनी ने अपने ट्रायल के आंकड़ों को जारी करते हुए दावा किया था.
- रूस का RDIF हर साल भारत में 10 करोड़ से अधिक स्पुतनिक वी की डोज़ बनाने के लिए करार कर चुका है.
20396. Nitin Gadkari inaugurates & lays foundation stone of 46 National Highway Projects in Karnataka
Infrastructural Development and Government Schemes
->
Highways and Roads
English
India
Financial Express
|
- Union Minister Nitin Gadkari inaugurated and laid foundation stone of 46 National Highway (NH) projects in the state of Karnataka with an investment of Rs 19,930 crore.
- NH Projects of a total length of 238 kilometres with an investment of Rs 3,972 crore will improve the inter state road connectivity from Karnataka to the states of Maharashtra and Goa.
- The NHs will provide connectivity to heritage monuments in the state of Karnataka which will give a boost to the tourism sector as well as create sustainable employment opportunities in the state
20397. भारत में पर्याप्त है कोविड वैक्सीन की उत्पादन क्षमता, जानें-कितनी कंपनियां बना रहीं टीका?
India Fights Corona: Vaccination Drive and Initiatives
Hindi
India
Aaj Tak
|
- कोविड वैक्सीन के करीब 11 करोड़ डोज लगाए जा चुके हैं. वैक्सीन के शॉर्टेज होने की भी कई खबरें आई हैं.भारत में COVID-19 के कुल टीका उत्पादन करने की क्षमता तो देश के लिए पर्याप्त है ही, हम दूसरे देशों को निर्यात भी कर सकते हैं.
- 2021 की तीसरी तिमाही तक भारत को पांच और टीके मिल सकते हैं. अहमदाबाद की Zydus Cadila अपने ZyCov-D टीके के तीसरे चरण के ट्रायल में लगी है. कंपनी की योजना कुल मिलाकर 25 करोड़ डोज सालाना के उत्पादन की है.
- हैदराबाद की बायोलॉजिकल ई ने जॉनसन ऐंड जॉनसन के COVID-19 टीका के हर साल 60 करोड़ डोज तेयार करने का कॉन्ट्रैक्ट लिया है. यह सिंगल शॉट टीका अमेरिका में मंजूर हो चुका है और भारत में इसके क्लीनिकल ट्रायल की तैयारी चल रही है. भारत बायोटेक एक और टीके का क्लीनिकल ट्रायल कर रहा है जिसे नाक से लिया जा सकेगा.
- टीका उत्पादन वाली एक और कंपनी अरबिंदो फार्मा की फिलहाल कोविड-19 टीका लाने की योजना नहीं दिख रही, लेकिन कंपनी अपने टीका उत्पादन क्षमता को जून 2021 तक बढ़ाकर 22 करोड़ डोज सालाना करने की तैयारी कर रही है.
20398. Limited Sputnik V Doses by April-End In India, 850 Million Doses Annually
India Fights Corona: Vaccination Drive and Initiatives
English
India
NDTV
|
- Russian-made Covid vaccine Sputnik V, the third vaccine to be approved by India, will be manufactured by five pharma firms in the country and 850 million doses are going to be produced annually. limited doses are going to be available by the end of April.
- India's drug regulator, the Drugs Controller General of India or DCGI, approved the Russian vaccine after it got a green signal by a special committee - the Subject Expert Committee of the Central Drugs Standard Control Organization - on Monday as a lethal second wave sweeps the country.
- Manufactured in India by Dr Reddy's, Sputnik V has the highest effectiveness - 91.6 per cent -- after the Moderna and Pfizer shots. The vaccine is already in Phase 3 of clinical trials in India and Dr Reddy's had applied for emergency use approval of the vaccine in February.
- The RDIF has reached agreements with five pharmaceutical firms in the country - Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech - aimed at production of more than 850 million doses per year.
20399. Dr Reddy’s to start supply of imported Sputnik V in May, made in India products later
India Fights Corona: Vaccination Drive and Initiatives
English
Russian Federation
Mint
|
- Dr Reddy’s Laboratories will start supplying Sputnik V vaccines imported from Russia in May and tap locally sourced jabs as their production ramps up in India, two people aware of the development said.
- Pricing of the vaccine as well as how many doses will be supplied initially have not yet been decided. Negotiations between the government and the Hyderabad-based drugmaker, which is the sole licensing partner for the vaccine in India, are on.
- “The supply will start from May via the imported route, and ramp-up of made-in-India product will happen over time," one of the people cited above said.
- Dr Reddy’s is in a pact with Russian Direct Investment Fund (RDIF), the global commercializing partner for the vaccine, to conduct phase 2 and 3 trials and supply up to 250 million doses in the country.
20400. Maharashtra sugar mills submit bids to supply 111 crore litres of ethanol in current supply year
Bharat Economic Growth
->
Increasing Exports
English
India
Financial Express
|
- Sugar mills in Maharashtra have filed bids to supply 111 crore litres of ethanol to oil marketing companies (OMC) for the ethanol supply year (December-November) 2021-22.
- This is expected to divert over 12 lakh tonne of sugar in the state with most of the ethanol being produced either from B heavy, C heavy molasses or directly from cane syrup.
- OMCs have floated national tenders for supply of 465 crore litres. Till February-end, the OMCs have finalised supplies of 416 crore litres and letters of intent (LOIs) for 401 crore litres have been issued.
Click here to find 862 similar incidents of Bharat Economic Growth -> Increasing Exports